0
Antiviral strategies for emerging infectious diseases: Cayman Chemical
The emergence and global spread of SARS-CoV-2 has prompted scientific study on an unprecedented scale, with an urgent need for…
Browsing: Uncategorized
0
Nearly half of all SARS-CoV-2 infections may be asymptomatic
A recent analysis of COVID-19 cases suggests that up to 45% of SARS-CoV-2 infections may be asymptomatic. This highlights the need for expansive testing and contact tracing to quash the pandemic.
0
COVID-19 research round-up: May
This month’s research round-up covers a number of studies investigating hydroxychloroquine, along with a remdesivir study, the first Phase I vaccine clinical trial and an exploration of the burden of COVID-19 on the healthcare system.
0
Using a novel approach for malaria vaccine development – an interview with Jonathan Kurtis
In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
0
Database tracks over 200 clinical trials testing drugs against COVID-19
The Anticancer Fund has created an open-access, online database called Covid19db, which shows the COVID-19 clinical trials currently taking place. The database has detected over 200 clinical trials across 35 countries, testing 102 different investigational drugs.
0
Responding to COVID-19 with AI and machine learning
As a result of the the pandemic we face, life-and-death choices will be made and often, artificial intelligence and machine learning can be used to make objective and informed recommendations. This editorial explores the challenges faced by healthcare systems, and how AI and machine learning can improve decision-making.
0
Thousands of coronavirus cases prevented by China’s control interventions, analysis suggests
It’s a commonly known fact that the current global pandemic caused by the coronavirus originated in Wuhan, China. Over the first 50 days, a series of control measures were implemented to impede the spread, but were these measures effective?
0
FDA approves Merck & Co.’s Ebola vaccine Ervebo: January’s industry headlines
Take a look at the industry headlines from the last 2 months, including the FDA approval of Ebola vaccine Ervebo,…
0
Early Career Panellist: Louis Laurence
Research Associate at the University of East Anglia and Procarta Biosystems, Norwich, UK Louis is a Research Associate at the…
0
Early Career Panellist: Zoe Ross
PhD student, MRC Centre for Medical Mycology, University of Aberdeen, UK Zoe is a PhD student in the Lorenz lab…